caa a22 4500 445889322 CHVBK 20180317145610.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s00535-011-0446-2 doi (NATIONALLICENCE)springer-10.1007/s00535-011-0446-2 Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs—TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan [Elektronische Daten] [Takahisa Furuta, Tomohiko Shimatani, Mitsushige Sugimoto, Shunji Ishihara, Yasuhiro Fujiwara, Motoyasu Kusano, Tomoyuki Koike, Michio Hongo, Tsutomu Chiba, Yoshikazu Kinoshita] Backgrounds: Some non-erosive reflux disease (NERD) and reflux esophagitis (RE) patients are unresponsive to a proton pump inhibitor (PPI) at standard dose. We investigated the predictive marker of the efficacy of PPI for GERD patients including NERD and RE treated with standard and increased doses of a PPI. Methods: Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10mg once daily for 4weeks. The RPZ dosage was increased to 10mg twice daily for an additional 2weeks and again to 20mg twice daily for another 2weeks if heartburn was not relieved. Baseline characteristics and efficacy of RPZ were assessed on the basis of a heartburn diary and frequency scale for symptoms of GERD (FSSG). Results: Complete heartburn relief rates after 4weeks were 42.5% (31/73) and 67.9% (19/28) in NERD and RE groups, respectively, which rose to 68.9 and 91.7% after dose escalation. Multivariate analysis revealed that parameters associated with resistance to RPZ 10mg once daily were female, non-smoking, frequent heartburn, low score for question 4 (Q4) of the FSSG (subconsciously rubbing the chest), and high scores for Q3 (heavy stomach after meal) and Q7 (unusual sensation in the throat). Frequent heartburn and a high score for Q7 were associated with resistance to RPZ 20mg twice daily. FSSG scores of patients resistant to RPZ were significantly higher in comparison with responders before and during treatment. Conclusions: FSSG could predict response to a PPI for symptomatic GERD. Increase of RPZ dose is useful for treatment of GERD refractory to the standard dose of RPZ. Springer, 2011 NERD nationallicence GERD nationallicence FSSG nationallicence Rabeprazole nationallicence Furuta Takahisa Center for Clinical Research, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, 431-3192, Hamamatsu, Japan aut Shimatani Tomohiko Department of General Medicine, Hiroshima University Hospital, Hiroshima, Japan aut Sugimoto Mitsushige First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan aut Ishihara Shunji Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Japan aut Fujiwara Yasuhiro Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Kusano Motoyasu Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Japan aut Koike Tomoyuki Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Hongo Michio Departments of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan aut Chiba Tsutomu Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan aut Kinoshita Yoshikazu Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Japan aut Journal of Gastroenterology Springer Japan 46/11(2011-11-01), 1273-1283 0944-1174 46:11<1273 2011 46 535 https://doi.org/10.1007/s00535-011-0446-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-011-0446-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Furuta Takahisa Center for Clinical Research, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, 431-3192, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Shimatani Tomohiko Department of General Medicine, Hiroshima University Hospital, Hiroshima, Japan aut NATIONALLICENCE 700 1- Sugimoto Mitsushige First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan aut NATIONALLICENCE 700 1- Ishihara Shunji Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Japan aut NATIONALLICENCE 700 1- Fujiwara Yasuhiro Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Kusano Motoyasu Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Japan aut NATIONALLICENCE 700 1- Koike Tomoyuki Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Hongo Michio Departments of Comprehensive Medicine and Psychosomatic Medicine, Tohoku University Hospital, Sendai, Japan aut NATIONALLICENCE 700 1- Chiba Tsutomu Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan aut NATIONALLICENCE 700 1- Kinoshita Yoshikazu Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/11(2011-11-01), 1273-1283 0944-1174 46:11<1273 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer